PPARA and metabolic dysfunction-associated steatotic liver disease: KEGG enrichment analysis revealed that leflunomide mainly regulated DEGs within pathways related to lipid metabolism (such as oxidative phosphorylation, non-alcoholic fatty liver disease, biosynthesis of amino acids, peroxisome proliferators-activated receptors (PPAR) signaling pathway, fatty acid metabolism, cholesterol metabolism, and fatty acid degradation) (Figure 2H).